CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on Advancements of Proprietary Biosynthesis Technology
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be further functionalized to produce any of the 90+ cannabinoids that occur naturally in the cannabis plant. “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed,” Eric A. Adams, president and CEO of InMed, stated in…